Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

UltiPace™ Pacing Lead

Robust Stylet-Driven Leads for Left Bundle Branch Area Pacing

Important Safety Information
 CLINICAL EVIDENCE 
Join Our Email List

Pioneering Innovation in LBBAP

Experience the innovation of the UltiPace Pacing Lead – Abbott's latest breakthrough and FDA-approved stylet-driven lead for left bundle branch area pacing (LBBAP). Engineered for superior performance in the pursuit of continuous innovation.1

UltiPace cross section

Connect with your Abbott Representative to learn more about LBBAP and stay informed about training opportunities. You can also sign up to receive updates on UltiPace Pacing Lead LBBAP clinical advancements.

Contact your Abbott Rep
Sign up for updates

Proven Design Evolved

UltiPace cross section

vs. Tendril™ STS1

3X

Increase in abrasion resistance

3.5X

Increase in lead crush resistance

vs. Tendril MRI™ 1

2.2X

Increase in abrasion resistance

2.6X

Increase in lead crush resistance

Discover the Clinical Evidence

Explore Dr. Bernabei's insights from Heart Rhythm 2024, including the efficacy and benefits of continuous unipolar pacing and impedance monitoring, and why not all stylet-driven leads are the same.

Review Clinical Evidence

Demonstrated LBBAP Success and Safety


Composite
success
rate2*

93% circle

of patients not experiencing
LBBAP-related adverse effects at  6 months post-implant.2

99.5% circle

Resistant to Distal Fatigue Failure

UltiPace Pacing Leads have a robust distal lead tip without a flexible zone that helps reduce stress on the conductors and the chance for distal fatigue failure compared to competitive leads.3

Ulipace pacing leads

Zero Helix Retraction

The Helix Locking Tool is a proven solution to lock an extended helix during tissue burrowing without retraction.3

UltiPace cross section

The Helix Locking Tool aids with lead fixation by providing control over the extension and retraction of the helix.

The Helix Locking Tool helps deploy the active fixation helix and hold it in place

Improved Torque Transmission with Fewer Rotations

 

Improvement in torsional stiffness when using UltiPace Pacing Leads compared to LBBAP-approved lumenless pacing leads.3

94% circle

Torque being applied to UltiPace lead body in LBBAP procedure.

Ensuring optimal slack during stylet retraction is key to preventing complications


Continuous Unipolar Pacing and Impedance Monitoring

Provides the user with uninterrupted feedback to help achieve optimal results.4

Stay Informed

Sign up to hear about our technology, education opportunities, and more.

Join Our Email List

Read the Latest Blog Article

Stay up to date with recent news, product highlights, and case studies.

Visit the Abbott CRM Blog

References

*Composite success rate of acceptable capture thresholds and sense amplitudes for LBBAP at 6 months post-implant.

  1. Abbott. Data on File. Item: 91010074 Ver A.
  2. Abbott. Left Bundle Branch Area Pacing Study. Item: ARTEN600334504 A.
  3. Abbott. Data on File, Engineering Technical Report. Item: 90994484 Ver D.
  4. Burri, H., Jastrzebski, M., Cano, O., Curila, K., Pooter, J. de, Huang, W., Israel, C., Joza, J., Romero, J., Vernooy, K., Vijayaraman, P., Whinnett, Z., & Zanon, F. (2023). EHRA clinical consensus statement on conduction system pacing implantation: Executive summary. endorsed by the Asia-Pacific Heart Rhythm Society (APHRS), Canadian heart rhythm society (CHRS) and Latin-American heart rhythm society (LAHRS). Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. https:// pubmed.ncbi.nlm.nih.gov/37061850/

Indications:

UltiPace™ leads are indicated for use in combination with a compatible pacemakers, implantable cardioverter defibrillator (ICDs) or cardiac resynchronization therapy (CRT-P/CRT-D) to provide sensing and pacing for the management of chronic symptomatic bradycardia and various atrioventricular conduction abnormalities in patients who experience syncope, presyncope, fatigue, disorientation due to arrhythmia/ bradycardia, or any combination of these symptoms. The UltiPace leads are implanted transvenously in either the right atrium, the right ventricle or the left bundle branch area.

MAT-2403244 v4.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-1900882 v13.0